• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 3rd July 2018

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

We conducted a literature review in order to identify whether long-term cancer survivors’ quality of life is comparable to that of the general population. Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

We conducted a literature review in order to identify whether long-term cancer survivors’ quality of life is comparable to that of the general population.

Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.
 
In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. 
 
This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age-/sex-matched population samples. The search strategy initially focused on identifying studies that assessed QoL in LTCS treated with immunotherapy, but the lack of studies necessitated a broader approach (i.e. any treatment type).
 
In total, 20 papers were included in the review, representing 23 studies. The studies covered a range of different cancers, with the majority collecting data from over 100 LTCS. LTCS included in the studies were more likely to have experienced early-stage cancer relative to late-stage cancer. Of the included studies, just under half (n=11) compared the QoL of a sample of LTCS and the QoL of a control group. Only one of these studies concluded that the evidence suggested that QoL was worse for LTCS relative to the control group.
 
The majority of studies that made explicit comparisons between LTCS and the general population suggested that levels of QoL in the two groups are quite similar. This could provide some evidence to support an argument for applying general population utilities to LTCS in economic models for cancer treatments.
 
It might be that cancer treatment is effective in restoring patients to a high level of QoL in the long-term. However, it is also possible that cancer patients ‘adapt’ to their condition over the long-term, though no studies explored this in detail. Alternatively, individuals with cancer may improve their lifestyle following diagnosis, which could improve their QoL in the long-term. However, evidence of lifestyle change is mixed in the included studies.
 
There are potential limitations to the data. This could include selection bias, where a fully representative sample cannot be recruited. In this case, it could be that healthier LTCS were more likely to have been included in the studies. In addition, the reporting and analyses conducted were of a low quality in some of the studies.
 
Notwithstanding the very limited evidence base and potential limitations, of the studies reporting comparisons with population norms, the majority provided evidence that the QoL of LTCS is similar to that of the general population. However, it is unclear how generalisable the results are, due to the different study settings. 
 
Therefore, care is required in asserting that general population utilities could be used to represent LTCS in economic models. Further research is required in a broad range of cancer and treatment types to provide a stronger understanding of QoL in LTCS. In particular, there is a need for more data on the QoL of LTCS who were treated with immunotherapy for advanced/metastatic disease. 
 
This study was undertaken by Patricia Cubi-Molla, David Mott, Koonal Shah, Mike Herdman and Nancy Devlin, in collaboration with Yvonne Summers of The Christie and Manchester University NHS Foundation Trusts. The study was funded by Roche Products Ltd. 
 
Download the full report here.
 
For more information about OHE’s research on this topic, contact Koonal Shah.
 
Citation
 
Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N. 2018. Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report, London: Office of Health Economics. RePEc
 
Related Research
 
Lorgelly, P.K. and Neri, M. 2018. Survivorship Burden for Individuals, Households and Society: Estimates and Methodology. Journal of Cancer Policy, 15(B), pp.113-7. DOI
 
Devlin, N., Lorgelly, P. 2017. QALYs as a Measure of Value in Cancer. Journal of Cancer Policy, 11, pp.19-25. DOI
 
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Consulting Reports

Related News

  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!